PrimeRFP
PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50119F33009IDIQ for biological nonclinical services — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent HHSO100201600004I. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Mar 31, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Glaxosmithkline LLC
Recipient
Mar 31, 2025
PoP end
$84K
Obligated
$18.2M
Potential
325414
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract number75A50119F33009
Also listed asHHSO100201600004I-75A50119F33009
AgencyBarda - Aspr / Daappo / Barda Dcma
Awarding officeBarda - Aspr / Daappo / Barda Dcma
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS325414

No full NAICS 325414 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVHHSO100201600004I
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
Related solicitation15100SOL00003
PoP startAug 28, 2019
PoP end (current)Mar 31, 2025
Obligated$84K
Current value$18.2M
Potential value$18.2M

IDIQ for Biological Nonclinical Services is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $18.2M ($84K obligated). Current period of performance ends Mar 31, 2025. Last award drew 1 bidder. Place of performance: DURHAM NC. Related solicitation 15100SOL00003.

Idiq for biological nonclinical services. Latest action is a modification.

Recompete timing

Public
● Past PoP end (568 days ago)

Current PoP ended Mar 31, 2025 (568 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Want the durability read on 75A50119F33009? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile →

Related awards

Same parent · incumbent
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…
$493K
Oct 29, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
15F06726F0000234
GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187
$113K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027
75A50124F61013
THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …
$15.4M
Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50119F33009?

75A50119F33009 (IDIQ for biological nonclinical services) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $18.2M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50119F33009?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50119F33009 to Glaxosmithkline LLC (potential $18.2M).

Who is the incumbent on 75A50119F33009?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Mar 31, 2025.

When does Glaxosmithkline LLC’s 75A50119F33009 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 31, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50119F33009? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50119F33009